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We examined how a common therapy that includes
clarithromycin affects normally colonizing Staphylococcus
epidermidis. Samples from the nostrils of 5 patients receiv-
ing therapy were collected before, immediately after, 1 year
after, and 4 years after treatment. From each patient and
sample, S. epidermidis strains were isolated and analyzed
for clarithromycin susceptibility and presence of the
erm(C) gene. We show that macrolide-resistant strains of
S. epidermidis were selected during therapy and that the
same resistant strain may persist for 4 years, in the
absence of further antimicrobial treatment.
T
he emergence and spread of drug-resistant bacteria
pose a serious threat to global public health (1,2), and
the normal biota constitutes a potential reservoir of resist-
ance genes that can spread to invading pathogens (3,4). A
gene (aphA-3) that confers resistance to amikacin and
kanamycin in Campylobacter spp. may have originated
from the gram-positive Enterococcus,  Streptococcus, or
Staphylococcus spp. (4). Similarly, aadE and tet(O), which
encode streptomycin and tetracycline resistance, respec-
tively, have been found in Campylobacter spp. but are con-
sidered to have been transferred from gram-positive
bacteria (4). Moreover, parts of the mosaic penicillin-bind-
ing protein genes of Streptococcus pneumoniae that confer
penicillin resistance are likely to originate from viridans
streptococci, which tend to be more resistant (5), and the
mecA gene that renders Staphylococcus aureus resistant to
all  β-lactams likely originated in coagulase-negative
staphylococci (6).
Staphylococcus epidermidis, a coagulase-negative
staphylococcus, is a major component of the normal
human biota (7). Large populations (103–106 CFU/cm2) of
S. epidermidis are commonly found in the anterior nares
and the axillae (7). Coagulase-negative staphylococci have
been increasingly recognized as important nosocomial
pathogens (8), affecting immunocompromised patients or
those with indwelling devices, such as joint prostheses,
prosthetic heart valves, and central venous catheters (8,9).
Since the infections associated with S. epidermidis are
chiefly acquired during hospitalization, it is not surprising
that they are increasingly resistant to antimicrobial drugs
(10). Macrolide resistance in S. epidermidis is commonly
caused by erm genes (10), whose products dimethylate a
23S rRNA adenine residue, preventing macrolide binding
to the 50S ribosomal subunit (11,12). In S. epidermidis,
erm(C), which induces high-level macrolide resistance,
predominates (13,14).
In this study, we have assessed how a commonly used
therapy that includes clarithromycin affects the normal
microbiota of S. epidermidis. We show that a 1-week
course of clarithromycin selects for macrolide-resistant S.
epidermidis that may persist up to 4 years after treatment.
Methods
During a cohort study that examined eradication of
Helicobacter pylori by a combination therapy that includ-
ed clarithromycin, we chose 5 patients in order to study
macrolide resistance in S. epidermidis. In the larger study,
all patients were colonized with H. pylori and had either a
duodenal or gastric ulcer, for which a 7-day course of clar-
ithromycin 250 mg twice per day (b.i.d.), metronidazole
400 mg b.i.d., and omeprazole 20 mg b.i.d. was given. We
excluded patients who had previously been treated for H.
pylori or who had received any antimicrobial treatment
within the prior 4 weeks. The control group included 5
patients with dyspeptic symptoms who had not received
any antimicrobial treatment. During the 4-year course of
this study, no other antimicrobial treatment was allowed.
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Samples from the nares of each patient were collected
1 day before treatment, 3–7 days immediately after, 1 year
later, and 4 years later. All samples were stored at –70°C
until analyzed. From each study patient and each sample,
10 independent colonies of S. epidermidis were isolated on
Columbia blood agar plates (Difco, Baltimore, MD, USA)
and verified by Gram staining, positive catalase, negative
DNase, negative mannitol, and negative trehalose testing.
DNA was extracted from the bacterial strains with the
DNeasy Tissue kit (Qiagen, Hilden, Germany). MIC of
clarithromycin was measured with the Etest (AB Biodisk,
Solna, Sweden), as recommended by the Swedish
Reference Group for Antibiotics.
The erm(C) gene was detected as described (13), by
using primers ermC1/C2 5′-GCTAATATTGTTTAAA-
TCGTCAATTCC-3′ and 5′-GGATCAGGAAAAGGA-
CATTT-3′ but with the following modifications: each
polymerase chain reaction (PCR) contained 25 µL master
mix (PCR Master, Roche, Penzberg, Germany), 30 pmol
of each primer, 14 µL distilled water, and 5 µL DNA sam-
ple. The amplified 572-bp product was separated by elec-
trophoresis on a 1.5% agarose gel.
For pulsed-field gel electrophoresis (PFGE), bacterial
cells were harvested by centrifugation from 3 mL
overnight cultures in brain-heart infusion broth and resus-
pended in 3 mL Tris-HCl buffer (pH 7.6). The bacterial
suspension (150 µL) was mixed with 150 µL 2% agarose
(Sigma, St. Louis, MO, USA) in Tris-HCl buffer and used
for making the gel plugs. The plugs were incubated at
35°C overnight in 4 mLLysis 1 buffer (6 mmol/LTris-HCl
[pH 7.6], 1 mol/L NaCl, 100 mmol/L EDTA [pH 7.5],
0.5% Brij 58, 0.2% deoxycholate, 0.5% sodium lauryl sar-
cosine [Sarcosyl, Kodak International Biotechno-logies,
New Haven, CT, USA], 1 mg/mL lysozyme [Life
Technology, Sigma-Aldrich, Steinheim, Germany], and 7
µg/mL lysostaphin [Sigma]), then incubated overnight at
55°C in 4 mL Lysis 2 buffer (1% sodium lauryl sarcosine
[Sarcosyl], 0.5 mol/L EDTA [pH 9.5], and 50 µg/mL
Proteinase K [Roche Diagnostics Corporation,
Indianapolis, IN, USA]). The plugs were washed 3 times
for >30 min at 35°C in 4 mLof Tris-EDTAbuffer. A3-mm
slice of each gel plug was incubated overnight at 25°C
with  SmaI (Life Technology, Invitrogen, Carlsbad, CA,
USA) and buffer, then placed in the wells of a 1.0%
agarose gel (Ultra pure agarose, Life Technology,
Invitrogen), sealed with 1.0 % agarose, and put in 0.5×
Tris-borate-EDTA buffer. Electrophoresis (Gene Path
Electrophoresis System, Bio-Rad Laboratories, Inc.,
Hercules, CA, USA) was performed with the following
conditions: 5–60 s switch interval with a voltage gradient
of 6 V/h at an angle of 120° for 23 h. After electrophore-
sis, the gel was stained with ethidium bromide for 30 min,
destained in distilled water for 1 h, and DNA was visual-
ized under UV light (Gel doc 1000, Bio-Rad Laboratories,
Inc.). The restriction fragment profiles were interpreted by
comparison with each other, with a reference S. aureus
strain  NCTC 8325, and with a λ phage DNA standard
(New England Biolabs, Beverly, MA, USA). 
Results
At 1 day before treatment, all 5 patients in the treatment
group harbored clarithromycin-susceptible (MIC <0.5
µg/mL) S. epidermidis among the 10 independent colonies
examined. In 4 patients, all 10 isolates were susceptible,
but in the fifth patient 2 isolates were highly resistant (MIC
>256 µg/mL) because erm(C) was present. Immediately
after completing treatment, 4 of 5 patients displayed high-
level clarithromycin-resistant (MIC >256 µg/mL) isolates
(Table 1). The other isolates from this time point were
either resistant with lower MIC values (16–96 µg/mL) or
susceptible. Highly resistant isolates could be detected 1
year after treatment in 4 patients and 4 years after treat-
ment in 3 patients. All highly resistant isolates harbored
erm(C), as determined by PCR. In the controls, who did
not receive any antimicrobial treatment, no selection of
resistant staphylococci was detected. However, in control
4, 1 highly resistant isolate was detected at the first time
point. In the same control, 2 of 10 isolates were highly
resistant at the second time point, but no resistance was
detected at the 1- and 4-year follow-ups. In control patient
5, all isolates were susceptible, except 5 resistant isolates
detected at the 4-year follow up (Table 2).
Isolates obtained from patients 1 and 2, chosen to
investigate the clonality of resistance, were genotyped by
pulsed-field gel electrophoresis (PFGE). Before treatment,
each patient carried 5 different S. epidermidis strains
among the 10 colonies tested. In patient 1, no highly resist-
ant isolates were detected before treatment. However,
immediately after treatment, 2 of 10 isolates were highly
resistant, both defined as strain H. Based on PFGE pat-
terns, strain H was detected in 8 of 10 isolates 1 year after
treatment and in 4 of 10 isolates 4 years after treatment
(Table 1). Strain G, which was susceptible to clar-
ithromycin, was present immediately after treatment and 4
years later. Two of the pretreatment strains (B and C) were
detected 4 years after treatment.
For patient 2, from whom 2 highly resistant isolates
with the same profile (N) were detected before treatment,
PFGE showed 2 distinct resistant strains (N and S) to be
present immediately after treatment. Clone N was detected
in 8 of 10 isolates 1 year after treatment and in 3 of 10 iso-
lates 4 years after treatment. Susceptible strains P and Q,
which were present pretreatment, were isolated again 4
years after treatment. Thus, after treatment in both cases,
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ed for 4 years, in the absence of further selection pressure,
and that both resistant and susceptible strains were present
4 years after treatment (Table 1).
In a similar manner, the isolates from 2 controls were
genotyped (Table 2). In control 1, at least 5 different strains
were present at the start of the study. After 1 year, the com-
position had changed, and after 4 years, a new strain pre-
dominated in the flora. In control 2, we initially detected 3
different strains. These strains were also represented at
each time point and predominated at 4 years. Thus, 1 con-
trol showed stable populations, whereas the other showed
a dynamic state in the absence of treatment. 
Discussion
Since antimicrobial drugs do not distinguish between
pathogenic and colonizing bacteria, our indigenous biota is
affected every time a drug is given (3,15). Resistance
development in staphylococci that normally colonize the
skin has previously been observed after antimicrobial pro-
phylaxis or treatment (16–18). Depending on mechanism,
resistance can be selected de novo, exist in the pretreat-
ment biota, or be acquired, especially in hospital environ-
ments.
In this study of the effect of a 1-week course of clar-
ithromycin on indigenous S. epidermidis populations, we
show that macrolide-resistant S. epidermidis strains are
selected during therapy and that, without further selection,
resistant clones can persist for up to 4 years. This finding
is important for several reasons. First, although S. epider-
midis belongs to the normal cutaneous microbiota, it may
be a pathogen, especially in hospitalized patients (8); sta-
bly resistant populations increase the risk for treatment
failure. Second, resistance in the normal microbiota might
contribute to increased resistance in higher-grade
pathogens by interspecies genetic transfer. Since the popu-
lation size of the normal microbiota is large, multiple and
different resistant variants can develop, which increases
the risk for spread to populations of pathogens. Persisting
populations of resistant microbiota further enhance trans-
fer risk, especially if the selecting agent is used for treat-
ment. Third, antimicrobial drugs may affect the stability of
residential populations.
Whether a resistant population persists is mostly deter-
mined by the fitness and transmission costs of resistance
(19,20). Most resistance involves a cost (21–24), but
resistance may occur without detectable cost (25). If most
resistance is costly for bacteria, resistant populations
should decline once the selective antimicrobial pressure is
removed. However, mutations may arise that compensate
for the fitness cost, restoring the bacteria’s fitness without
reversion of the resistant phenotype. This phenomenon,
compensatory evolution, is considered to be relevant to
stabilizing resistant populations (26). Other important
mechanisms that could stabilize resistant populations are
no-cost resistance mutations (25) and genetic linkage with
adjacent genes. Despite substantially decreased sulfon-
amide use in the United Kingdom from 1991 to 1999,
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Staphylococcus epidermidis and ClarithromycinEscherichia coli resistance to sulfonamides remained high
(39.7% in 1991, 46.0% in 1999) because sulfonamide
resistance was linked to other resistance genes that contin-
ued to be under selective pressure (27). In poultry, since
vanA can be co-selected with erm(B) in Enterococcus
hirae isolates (28), vancomycin resistance can be main-
tained by using macrolides, despite excluding avoparcin
from animal feed. Thus, the stability and maintenance of
antimicrobial drug resistance depends on the magnitude of
selective pressure, compensatory evolution, no-cost asso-
ciated resistance, and genetic linkage with co-selected
resistance genes.
In our study, resistant isolates persisted long after drug
treatment was completed. However, a variation in length
of persistence between the patients was observed. Whether
this variation is related to different costs associated with
erm(C) carriage or different extents of genetic compensa-
tion for an initial cost cannot be concluded from current
data. The observed variation in persistence of resistance
could further be affected by the degree of recolonization
and transient colonization of new strains during the 4-year
study period. Although recolonization with S. epidermidis
is presumably low, it can be enhanced by, for example,
nosocomial spread during hospital stays (29). That indige-
nous S. epidermidis populations may naturally change in
composition over time was reflected in the control group.
According to the PFGE profiles from controls 1 and 2,
populations of S. epidermidis can either remain stable for
4 years or show a more dynamic state, with new strains
appearing over time. A change in the composition of the
flora was also observed in control 5, in whom 5 resistant
isolates appeared in the susceptible flora after 4 years.
Since this patient did not receive any antimicrobial drugs
during the study period, this finding is likely due to recol-
onization or transient colonization of a strain from the
environment. However, most importantly, although a few
resistant isolates were detected among the controls, no
selection of resistant S. epidermidis occurred over the 4-
year study period, as was observed in the treated patients.
In conclusion, antimicrobial drug treatment affects our
indigenous microbiota and can give rise to long-term colo-
nization with resistant populations. Our results show that as
part of a combination therapy, a 7-day course of clar-
ithromycin resulted in macrolide-resistant S. epidermidis
that persisted up to 4 years without any further selection. In
total, these observations suggest that selection of resistance
in our microbiota after short antimicrobial drug courses
may not be a rare phenomenon. However, the extent, to
which other antimicrobial treatment regimens select for
resistant S. epidermidis remains to be investigated.
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